Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alisertib + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Puma Biotechnology
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Alisertib + paclitaxel is a combination therapy consisting of alisertib, an oral small molecule inhibitor of Aurora kinase A (AURKA), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. Alisertib inhibits AURKA, a serine/threonine kinase involved in mitotic progression and tumor cell proliferation. Paclitaxel disrupts mitotic spindle assembly by stabilizing microtubules. The combination is designed to synergistically impair cancer cell division and survival in rapidly proliferative tumors. This regimen has been investigated in multiple clinical trials for advanced solid tumors including high-grade neuroendocrine tumors (NETs), small cell lung cancer (SCLC), metastatic breast cancer (both hormone receptor positive/HER2-negative and triple negative subtypes), as well as ovarian cancer. Clinical studies have shown that the combination can improve progression-free survival compared to single-agent therapy with manageable toxicity profiles[1][4][5].
- Other names
- alisertib plus paclitaxelalisertib and paclitaxelMLN8237 + paclitaxel
02
Targets
AURKA (Aurora kinase A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on alisertib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alisertib + paclitaxel.